GI
DNLI icon

GAMMA Investing’s Denali Therapeutics DNLI Stock Holding History

GAMMA Investing’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$46.2K Buy
2,236
+687
+44% +$16.1K ﹤0.01% 2421
2026
Q2 		$39.8K Buy
1,549
+121
+8% +$2.49K ﹤0.01% 2453
2026
Q1 		$27.4K Buy
1,428
+466
+48% +$9.27K ﹤0.01% 2549
2025
Q4 		$15.9K Buy
962
+233
+32% +$3.93K ﹤0.01% 2737
2025
Q3 		$10.6K Sell
729
-20
-3% -$287 ﹤0.01% 2855
2025
Q2 		$10.5K Buy
749
+164
+28% +$2.31K ﹤0.01% 2777
2025
Q1 		$7.95K Sell
585
-1,663
-74% -$31.9K ﹤0.01% 2863
2024
Q4 		$45.8K Sell
2,248
-90
-4% -$2.3K ﹤0.01% 1723
2024
Q3 		$68.1K Buy
2,338
+281
+14% +$6.96K 0.01% 1272
2024
Q2 		$47.8K Buy
2,057
+1,847
+880% +$35.5K 0.01% 1225
2024
Q1 		$4.31K Buy
210
+164
+357% +$3.08K ﹤0.01% 2468
2023
Q4 		$736 Buy
+46
New +$911 ﹤0.01% 2879

Other funds holding DNLI

BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing's DNLI Position: Q3 2026 in Review

GAMMA Investing increased its Denali Therapeutics (DNLI) stake by 44% in Q3 2026, buying an estimated $16.1K and bringing the position to 2,236 shares worth $46.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2421.

GAMMA Investing first reported a position in DNLI in Q4 2023 and has held it in 12 quarters since. The position peaked at $68.1K in Q3 2024. 5 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • GAMMA Investing held 2,236 shares of Denali Therapeutics worth $46.2K as of Q3 2026.
  • GAMMA Investing bought 687 Denali Therapeutics shares in Q3 2026, an estimated $16.1K.
  • Denali Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2421 holding.
  • GAMMA Investing first reported a position in Denali Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's Denali Therapeutics position peaked at $68.1K in Q3 2024.
  • 5 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.